<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00828646</url>
  </required_header>
  <id_info>
    <org_study_id>CN156-012</org_study_id>
    <nct_id>NCT00828646</nct_id>
  </id_info>
  <brief_title>Safety Study of Multiple-dose of Gamma-secretase Inhibitor in Healthy Male Japanese and Healthy Elderly Japanese</brief_title>
  <acronym>JMAD</acronym>
  <official_title>Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-708163 in Healthy Male Japanese Subjects and a Comparison to Healthy Elderly Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics,&#xD;
      and pharmacodynamics following 14-day multiple oral doses BMS-708163 in healthy young male&#xD;
      Japanese and healthy elderly male and female Japanese subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Within 30 days after the follow-up evaluation on Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration</measure>
    <time_frame>Day 21</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BMS-708163 - Panel 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Age 20-45 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-708163 - Panel 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Age 20-45 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-708163 - Panel 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(age 65 or above)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-708163 - Panel 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(age 65 or above)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-708163</intervention_name>
    <description>Capsules, Oral, 50 mg, once daily, 14 days</description>
    <arm_group_label>BMS-708163 - Panel 1</arm_group_label>
    <arm_group_label>BMS-708163 - Panel 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-708163</intervention_name>
    <description>Capsules, Oral, 100 mg/day, once daily, 14 days</description>
    <arm_group_label>BMS-708163 - Panel 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-708163</intervention_name>
    <description>Capsules, Oral, 75 or 100 mg/day, once daily, 14 days</description>
    <arm_group_label>BMS-708163 - Panel 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules, Oral, once daily, 14 days</description>
    <arm_group_label>BMS-708163 - Panel 1</arm_group_label>
    <arm_group_label>BMS-708163 - Panel 2</arm_group_label>
    <arm_group_label>BMS-708163 - Panel 3</arm_group_label>
    <arm_group_label>BMS-708163 - Panel 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects as determined by no clinically significant deviation from normal in&#xD;
             medical history, physical examination, ECGs, and clinical laboratory determinations&#xD;
&#xD;
          -  Body Mass Index (BMI) of 19 to 25 kg/m2, inclusive. BMI = weight (kg)/ [height (m)]2&#xD;
&#xD;
          -  Men, ages 20 to 45, and men and women [not of childbearing potential (i.e., who are&#xD;
             postmenopausal or surgically sterile)], ages 65 or older. Women are considered&#xD;
             surgically sterile only if they have undergone a hysterectomy, bilateral tubal&#xD;
             ligation, or bilateral oophorectomy. Women are considered postmenopausal only if they&#xD;
             have had amenorrhea for ≥12 consecutive months, or for women on hormone replacement&#xD;
             therapy (HRT), if they have a documented serum follicle stimulating hormone (FSH)&#xD;
             level &gt; 35 mIU/mL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  WOCBP&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Women with a positive pregnancy test on enrollment or prior to administration of&#xD;
             investigational product&#xD;
&#xD;
          -  Sexually active fertile men not using effective birth control if their partners are&#xD;
             WOCBP&#xD;
&#xD;
          -  Any significant acute or chronic medical illness&#xD;
&#xD;
          -  Any current or recent? medical history of gastrointestinal disease that may affect&#xD;
             evaluation of study treatment&#xD;
&#xD;
          -  History of recent major surgery or gastrointestinal surgery that may impact on&#xD;
             evaluation or absorption of study drug&#xD;
&#xD;
          -  History of blood donation or blood transfusion within 4 weeks prior to the study&#xD;
             treatment&#xD;
&#xD;
          -  Intolerance to oral medication or venous access&#xD;
&#xD;
          -  QTc interval (Bazett's correction) &gt;500 ms at screening&#xD;
&#xD;
          -  Smoking more than 10 cigarettes per day&#xD;
&#xD;
          -  Recent (within 6 months) drug or alcohol abuse as defined in DSM IV&#xD;
&#xD;
          -  Any other sound medical, psychiatric and/or social reason as determined by the&#xD;
             investigator&#xD;
&#xD;
          -  Subjects ≥ 65 yr are allowed to have age-related minimum or mild abnormalities in&#xD;
             vital sign (i.e. blood pressure) or laboratory tests (i.e. blood sugar, serum&#xD;
             cholesterol, or serum triglyceride) as far as they are not deemed signs or&#xD;
             consequences of illness or organ dysfunction and a subject of medical treatment&#xD;
&#xD;
          -  Evidence of organ dysfunction or any clinically significant deviation from normal in&#xD;
             physical examination, vital signs, ECG or clinical laboratory determinations&#xD;
&#xD;
          -  Positive urine screen for drugs of abuse&#xD;
&#xD;
          -  Positive blood screen for hepatitis C antibody, or HIV or hepatitis B antigen&#xD;
&#xD;
          -  Indicators of abnormal renal function at baseline: any urine protein&#xD;
&#xD;
          -  History of allergy to Gamma-Secretase Inhibitor or related compounds&#xD;
&#xD;
          -  History of any significant drug allergy&#xD;
&#xD;
          -  Prior exposure to BMS-708163&#xD;
&#xD;
          -  Exposure to any investigational drug or placebo within 4 weeks of study drug&#xD;
             administration&#xD;
&#xD;
          -  Use of any prescription drugs or over-the-counter acid controllers within 4 weeks&#xD;
             prior to study drug administration&#xD;
&#xD;
          -  Use of any other drugs, including over-the-counter medications and herbal&#xD;
             preparations, within 2 weeks prior to study drug administration&#xD;
&#xD;
          -  Subjects who are compulsorily detained for treatment of either a psychiatric or&#xD;
             physical (eg, infectious disease) illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>2320064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>January 23, 2009</study_first_submitted>
  <study_first_submitted_qc>January 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2009</study_first_posted>
  <last_update_submitted>January 6, 2011</last_update_submitted>
  <last_update_submitted_qc>January 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <keyword>Healthy Subjects</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

